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Abstract
Background—In 2011, the Advisory Committee for Immunization Practices (ACIP) 
recommended routine use HPV vaccine for male adolescents.
Methods—We used the 2013 National Immunization Survey-Teen (NIS-Teen) data to assess 
HPV vaccine uptake (≥1 dose) and series completion (≥3 doses). Multivariable logistic regression 
analysis and a predictive marginal model were conducted to identify independent predictors of 
vaccination among adolescent males aged 13–17 years.
Results—HPV vaccination coverage with ≥1 dose was 34.6% while series completion (≥3 doses) 
was 13.9%. Coverage was significantly higher among non-Hispanic blacks and Hispanics 
compared with non-Hispanic white males. Multivariable logistic regression showed that 
characteristics independently associated with a higher likelihood of HPV vaccination (≥1 dose) 
included: being non-Hispanic black race or Hispanic ethnicity, having mothers who were 
widowed, divorced, or separated, having 1–3 physician contacts in the past 12 months, a well-child 
visit at age 11–12 years, having one or two vaccination providers, living in urban or suburban 
areas, and receiving vaccinations from more than one type of facility (p<0.05). Having mothers 
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with some college or college education, having a higher family income to poverty ratio, living in 
South or Midwest, and receiving vaccinations from all STD/school/teen clinics or other facilities 
were independently associated with a lower likelihood of HPV vaccination (p<0.05).
Conclusions—Following recommendations for routine HPV vaccination among male 
adolescents, uptake in 2013 was low in males. Increased efforts are needed to improve vaccination 
coverage, especially for those who are least likely to be vaccinated.
Introduction
Human papillomavirus (HPV) is the most common sexually transmitted infection in men 
and women in the United States (1, 6). More than 50% of sexually active men and women 
will acquire HPV infection in their lifetime (2). One recent study showed that approximately 
79 million persons are currently infected with HPV, and 14 million persons are newly 
infected each year in the United States (4). Most infections cause no symptoms, but 
persistent infection may result in disease or cancer. Each year in the United States, an 
estimated 26,000 new cancers are attributable to HPV, about 17,000 in women and 9,000 in 
men (4, 5). HPV-related cancers in males include many anal, penile, and oropharyngeal 
cancers (6–10). HPV-associated oropharyngeal and anal cancers have increased among 
males (6, 9–11).
Vaccination is an important tool to prevent and control HPV infection and its complications 
(1). In 2006, quadrivalent HPV vaccine (HPV4) was licensed by the Food and Drug 
Administration (FDA) for use in females (1). In 2009, the Advisory Committee on 
Immunization Practices (ACIP) voted and provided guidance that the HPV4 vaccine may be 
given to males 9 through 26 years, noting that men who have sex with men (MSM) are 
particularly at risk for conditions associated with HPV infection (12, 13). In 2011, ACIP 
recommended routine use of HPV4 among males aged 11 or 12 years and recommended 
HPV4 for males aged 13–21 years who have not been vaccinated previously or who have not 
completed the 3-dose series (6). Previous study showed that early uptake of HPV 
vaccination of male adolescents was 1.4% in 2010, and 8.3% in 2011 (14).
We analyzed data from the 2013 National Immunization Survey-Teen (NIS-Teen) to evaluate 
HPV vaccination uptake, reasons for not receiving vaccination, and to identify factors 
independently associated with HPV vaccination among male adolescents aged 13–17 years. 
The results from this study may inform relevant interventions to increase vaccination 
coverage.
Methods
We analyzed data from the National Immunization Survey-Teen (NIS-Teen), a national, 
random-digit–dial (RDD) telephone survey sponsored by the Centers for Disease Control 
and Prevention (CDC). The objective of the NIS-Teen is to provide timely, detailed 
information regarding vaccination among adolescents aged 13–17 years for vaccines 
recommended by the ACIP, including HPV vaccine, and to evaluate factors associated with 
vaccination. Data are collected in the NIS-Teen in two-phases. In the first phase, a RDD 
household interview is conducted to identify households with age-eligible adolescents and to 
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collect demographic information from the parent or guardian on adolescent, maternal, and 
household characteristics. Also, the household interview included questions on the teen’s 
reported vaccination history, reasons for no intent of receiving vaccine among those who 
have not received HPV vaccination, and access to care. After completing the household 
interview, consent is requested to contact the immunization provider(s) to collect provider-
reported immunization records. If consent is obtained, adolescent’s vaccination providers are 
mailed a questionnaire to collect provider-reported vaccination histories of each 
recommended adolescent vaccine as well as any childhood vaccines. Regarding HPV 
vaccine, date of vaccination and type of HPV vaccines (HPV2, HPV4) from the provider 
record were collected. Among male adolescents 13–17 years, those who were reported by 
provider that they received unknown type of vaccine or HPV2 vaccine (0.67%, n=64) were 
considered receiving HPV4 vaccination since HPV4 is the only HPV vaccine that is 
recommended for male adolescents (6).
In 2013, the NIS-Teen sampling plan included independent samples of households with a 
land line and households with a cell phone (15, 16). In 2013, the Council of American 
Survey Research Organizations (CASRO) landline response rate was 51.1%. A total of 
18,246 adolescents with provider-reported vaccination records were included, representing 
59.5% of all adolescents from the landline sample with completed household interviews. 
The cellular-telephone sample CASRO response rate was 23.3%. A total of 12,225 
adolescents with provider-reported vaccination records were included, representing 54.5% of 
all adolescents from the cellular-telephone sample with completed household interviews (15, 
16). Our analysis was restricted to male adolescents aged 13–17 years.
Covariates were selected from survey questions to measure associations of HPV vaccination 
with age group, race/ethnicity, mother’s educational level, mother’s marital status, mother’s 
age, U.S. born status, poverty level, type of medical insurance, number of physician contacts 
within past 12 months, provider reported health-care visit at age 11–12 years, number of 
provider reported vaccination providers, facility type (public, private, hospital, STD/school/
teen clinics, mixed [including facilities in more than one category such as private, public, 
hospital, STD/school/teen clinics], and others [such as military, WIC clinics, and 
pharmacies]), metropolitan statistical area (MSA), and U.S. region. There were missing 
values for some of the variables listed above, and the proportions of missing value were 
small and ranged from 0.1% to 1.3%.
SUDAAN 11.0.1 (Software for the statistical analysis of complex sampling data, Research 
Triangle Institute, Research Triangle Park, NC) was used to calculate point estimates and 
95% confidence intervals (CIs) adjusted for the complex sample design of the NIS-Teen. All 
analyses account for the complex sampling plan of the NIS-Teen and the survey sampling 
weights (16). T-tests were used to examine associations with the significance level set at 
α<0.05. Multivariable logistic regression and predictive marginal models were conducted to 
derive the adjusted prevalence ratio (PR). The models were checked for multi-collinearity. 
All variables selected were included in the model. Additionally, Kaplan-Meier survival 
analysis was conducted to estimate the cumulative proportion of adolescents vaccinated over 
time by birth cohort. The NIS-Teen was approved by the Centers for Disease Control and 
Prevention, National Center for Health Statistics Research Ethics Review Board.
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Results
The 2013 NIS-Teen included a total of 9,554 male adolescents aged 13–17 years with 
sufficiently detailed provider data. Table 1 shows the demographic characteristics of the 
study population. Most were non-Hispanic white (54.3%), had mothers with more than a 
high school education (61.8%), had mothers who are currently married (66.7%), were born 
in the U.S. (95.3%), were living in a household with an income >133% of the federal 
poverty level (66.0%), had one vaccination provider (50.7%), had at least one physician 
contact within the past year (82.0%), and had all private reported vaccination providers 
(52.2%).
HPV vaccination uptake (≥1 dose)
Overall, HPV vaccination coverage with ≥1 dose was 34.6%, and coverage (≥1 dose) was 
significantly higher among non-Hispanic blacks (42.2%) and Hispanics (49.6%) compared 
with non-Hispanic whites (26.7%) (p<0.05) (Table 2).
In bivariable analyses, among male adolescents, other characteristics that were significantly 
associated with a higher level of HPV vaccination coverage compared with the referent 
group included: mother of adolescent being never married, widowed, divorced, or separated, 
being born outside the United States, being VFC eligible but not uninsured or with SCHIP 
insurance (the state children’s health insurance), having 2 or 3 physician contacts in the past 
12 months, having a well-child visit at age 11–12 years, having one or two vaccination 
providers, and living in urban or suburban areas (p<0.05). Those whose mothers had high 
school or more than high school education, those whose mother’s age was ≥45 years, those 
with an income to poverty ratio >133%, those living in the Midwest or South, and those 
receiving vaccinations from all STD/school/teen clinics or other facilities were 
characteristics associated with a lower level of HPV vaccination (Table 2).
HPV vaccination uptake (≥3 doses)
Overall, HPV vaccination uptake (≥3 doses) was 13.9%. Coverage (≥3 doses) was 
significantly higher among non-Hispanic blacks (15.7%) and Hispanics (20.3%) compared 
with non-Hispanic whites (11.1%) (p<0.05) (Table 3).
In bivariable analyses, among male adolescents, other characteristics that were significantly 
associated with a higher level of HPV vaccination coverage (≥3 doses) compared with the 
referent group included: having a well-child visit at age 11–12 years, and living in urban or 
suburban areas (p<0.05). A mother with a high school or more than high school education, 
income to poverty ratio between 133% and 503%, and being VFC eligible but not insured 
were characteristics associated with a lower level of HPV vaccination (≥3 doses) (p<0.05) 
(Table 3).
Factors associated with HPV vaccination based on multivariable logistic regression 
models
Multivariable logistic regression showed that characteristics independently associated with a 
higher likelihood of HPV vaccination (≥1 dose) included: being non-Hispanic black race or 
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Hispanic ethnicity, having mothers who were widowed, divorced, or separated, having 1 to 3 
physician contacts in the past 12 months, having a well-child visit at age 11–12 years, 
having one or two vaccination providers, living in urban or suburban areas, and receiving 
vaccinations from mix of facility types (p<0.05). Having mothers with some college or 
college education, those with a higher family income to poverty ratio, those living in South 
or Midwest, and those receiving vaccinations from all STD/school/teen clinics or other 
facilities were characteristics independently associated with a lower likelihood of HPV 
vaccination (p<0.05) (Table 2). Statistical tests found that multi-collinearity was not 
identified among all variables assessed in this multivariable logistic model.
Multivariable logistic regression showed that characteristics independently associated with a 
higher likelihood of HPV vaccination (≥3 dose) included: being non-Hispanic black race or 
Hispanic ethnicity, having a well-child visit at age 11–12 years, and living in urban or 
suburban areas (p<0.05). Income to poverty ratio between 322% and 503%, and being VFC 
eligible but not insured were characteristics that were associated with a lower level of HPV 
vaccination (≥3 doses) (p<0.05) (Table 3). Statistical tests found that multi-collinearity was 
not identified among all variables assessed in this multivariable logistic model.
Trends of HPV vaccination among male adolescents
Overall, HPV vaccination coverage among male adolescents significantly increased from 
2010 to 2013 (test for trend, p<0.05). In addition, among each birth cohort, the cumulative 
percent receiving HPV vaccination among male adolescents increased slowly before June 
2011 and increased considerably after June 2011, particularly, after December 2011 (Figure 
1, Figure 2).
Parent-reported reasons for non-receipt of HPV vaccination among male adolescents
The most common reason reported by parents for having no intent for their boys to receive 
HPV vaccination among those who have not received any HPV vaccinations was that the 
respondent thought their provider did not recommend it (24.0%). Other reasons included 
that it was not needed or not necessary (18.9%), lack of knowledge (16.4%), the adolescent 
was not sexually active (8.1%), and safety concern/side effects (7.3%) (Table 4). Percentages 
reported among males aged 13–15 years were similar with those aged 16–17 years (Table 4).
Discussion
Findings from our analysis show that HPV vaccine coverage (≥1 dose) among male 
adolescents aged 13–17 years was 34.6% and ≥3 HPV doses was 13.9%, approximately 1–2 
years after the quadrivalent HPV vaccine was routinely recommended by ACIP for male 
adolescents (6). Coverage increased steadily after the ACIP recommendation, but remained 
low, as about two-thirds of male adolescents were still unvaccinated with HPV in 2013.
Early uptake of HPV vaccine among male adolescents is similar to early uptake of other 
vaccines recommended for adolescents. Meningococcal conjugate vaccine (MCV4), 
Tetanus, diphtheria and acellular pertussis vaccine (Tdap), and HPV vaccine (female), three 
new vaccines recommended for adolescents in 2005, 2005, and 2006, had reported 
vaccination coverage levels of 10.8%, 11.7%, and 25.1% (approximately one year after 
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ACIP’s recommendations), respectively, for receipt of ≥ 1 dose (17–20). MCV4, Tdap, and 
HPV vaccination (female) coverage were 30.4%, 32.4%, and 37.2%, respectively, 
approximately two years after ACIP’s recommendations (17–20). Although HPV 
vaccination uptake in boys was similar to uptake in girls 1–2 years after ACIP 
recommendations were made, one might have expected uptake in boys to be higher in the 
same amount of time since providers already had the vaccine on stock (so no delays in 
obtaining supply) and they had experience with administering the vaccine.
Our analysis showed that HPV vaccination coverage among males significantly increased 
from 2010 to 2013 (test for trend, p<0.05). One previous study also indicated that early 
uptake of HPV vaccination (≥1 dose) of male adolescents increased from 1.4% in 2010 to 
8.3% in 2011 (14). Another study showed that HPV vaccination (≥1 dose) of Hispanic males 
13–17 years increased from 2.8% in 2010 to 31.7% in 2012 (21), and our study showed that 
the coverage (≥1 dose) among Hispanic males 13–17 years further increased to 49.6% in 
2013. The results from previous research and our study reflect the adoption of ACIP 
recommendations during this period. Studies have found that HPV vaccine awareness was 
lower among male adolescents and their parents (22) which may impact uptake of this 
vaccine. Continued monitoring will determine if HPV vaccination coverage continues to 
increase or levels off as has been observed for HPV vaccination of females (15, 23).
Racial and ethnic disparities were noted, with non-Hispanic black male adolescents having 
significantly higher HPV vaccine coverage (≥1 dose) compared with non-Hispanic white 
males. Disparities were also noted with Hispanics having significantly higher HPV vaccine 
coverage (both ≥ 1 dose and ≥3 doses) compared with non-Hispanic white males. This 
disparity remained after controlling for other factors. Racial and ethnic disparities in HPV 
vaccination were similar to those among female adolescents (22). HPV vaccination coverage 
was generally higher among teens living in poverty, which might reflect the VFC program’s 
(24) effectiveness at reaching these young persons. Further research is needed to better 
understand the factors associated with racial/ethnic differences in HPV vaccination coverage 
among male adolescents.
Several other characteristics, such as having more physician contacts in the past 12 months, 
and having a well-child visit at age 11–12 years were independently associated with HPV 
vaccination initiation, consistent with other vaccination studies among adolescents (25–28). 
Physician recommendations for vaccination are associated with a patient’s decision to get 
vaccinated (25–28). Persons who have more physician contacts may have more opportunities 
to discuss their vaccination status and receive vaccination.
Some barriers may hinder vaccine uptake. Our analysis indicated that the most common 
primary reasons for not receiving HPV vaccination among male adolescents 13–17 years 
were that their provider did not recommend HPV vaccination (24.0%), that the vaccine was 
not needed or not necessary (18.9%), lack of knowledge (16.4%), the adolescent was not 
sexually active (8.1%), and safety concern/side effects” (7.3%). These stated reasons for not 
receiving HPV vaccine indicate that parents may have limited knowledge regarding HPV 
vaccine and ACIP recommendations. To help facilitate discussions between clinicians and 
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parents, CDC has developed several resources, including a tips sheet with suggested 
language for talking with parents (29).
The Guide to Community Preventive Services has identified evidence based strategies to 
improve vaccination coverage, including standing orders programs, reminder/recall systems 
to notify clinicians and parents when a vaccine is due, and use of Immunization Information 
Systems (30). While these interventions may be helpful for adolescents who need to receive 
their second or third dose of HPV vaccine, it is not clear that they will be sufficient for 
improving initiation of the series. Additional efforts will be needed to improve provider 
practices and recommendation of this vaccine at age of 11–12 years to all adolescent boys 
and girls.
The findings in this study are subject to several limitations. First, household response rates 
were 51.1% (landline households) and 23.3% (cellular phone households), respectively. 
Only 59.5% (landline) and 54.5% (cellular telephone) of completed household interviews 
also had adequate provider-verified vaccination data. Some bias may remain after weighting 
adjustments designed to mitigate potential bias from incomplete data from the sample frame 
and non-response (31, 32). Second, some provider-confirmed vaccination histories might not 
include all vaccinations received (e.g., vaccinations administered in nontraditional settings 
such as emergency departments) and might have underestimated vaccination coverage.
One to two years after the vaccine was recommended for male adolescents, only 34.6% had 
initiated HPV vaccination (≥1 dose), and 13.9% had ≥3 HPV doses. Coverage increased 
steadily after the ACIP recommendation for routine vaccination of males, but remained low, 
as about two-thirds of male adolescents were still unvaccinated with HPV in 2013. To 
further increase HPV vaccination coverage, comprehensive strategies included: 1) providers 
should routinely assess the HPV vaccination status of their patients, especially when they 
have a well-child visit, to ensure that the adolescent is fully vaccinated and recommending 
catch-up vaccination and administering all age-appropriate vaccines during the same clinical 
encounter; 2) it is important to ensure all vaccine providers are knowledgeable about HPV 
vaccine recommendations for males and females, with provision for current information on 
efficacy and safety of vaccines; 3) reducing parental out-of-pocket expenses; 4) using media 
promotions and educational programs for parents to improve HPV awareness; and 5) efforts 
should be directed to provide comprehensive, accessible, and appropriate communication 
messages on HPV and HPV vaccine directed to male adolescent and parents (29, 30, 33). 
Additionally, the Affordable Care Act may help improve vaccination coverage since the 
expanded enrollment in public and private insurance programs expected from provisions of 
the Affordable Care Act is likely to improve access to health care services, including 
vaccination (34). Continued monitoring of HPV vaccination uptake among males is useful 
for evaluating vaccination campaigns and for planning and implementing strategies to 
increase vaccination coverage. Increased efforts are needed to improve HPV vaccination 
coverage for all adolescents to reduce HPV infections and related cancers.
ABBREVIATIONS
HPV Human papillomavirus
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ACIP Advisory Committee on Immunization Practices
FDA Food and Drug Administration
PR Prevalence ratio
95% CI 95% confidence interval
MSM Men who have sex with men
RDD Random-digit–dial
CDC Centers for Disease Control and Prevention
STD Sexual transmitted diseases
WIC Women, Infants, and Children
MSA Metropolitan statistical area
SCHIP State Children’s Health Insurance Program
NIS-Teen National Immunization Survey-Teen
VFC Vaccines for Children
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What’s know?
HPV is the most common sexually transmitted infection in the United States. More than 
50% of sexually active men and women will acquire HPV infection in their lifetime. In 
2011, HPV was recommended for routine use among male adolescents.
What’s added?
This is the first study to evaluate HPV vaccination coverage among male adolescents in 
the United States using provider reported vaccination data. HPV coverage was low 
among male adolescents, leaving a large population susceptible to HPV infection 
maturing into adulthood.
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Figure 1. 
Cumulative percent of HPV vaccination (≥1 dose) uptake over time by birth cohort among 
male adolescents 13–17 years, NIS-Teen, 2013
Total, born in 2000, born in 1999, born in 1998, born in 1997, born in 1996
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Figure 2. 
Cumulative percent of HPV vaccination (≥3 dose) uptake over time by birth cohort among 
male adolescents 13–17 years, NIS-Teen, 2013
Total, born in 2000, born in 1999, born in 1998, born in 1997, born in 1996
Lu et al. Page 13
Pediatrics. Author manuscript; available in PMC 2018 February 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lu et al. Page 14
TABLE 1
Sample characteristics of male adolescents aged 13–17 years in the United States, by demographic and access-
to-care variables--NIS-Teen 2013
Characteristic Sample %*
Total 9,554
Age (years)
 13–15 5,819 61.0 (59.1–62.8)
 16–17 3,735 39.0 (37.2–40.9)
Race/ethnicity
 Non-Hispanic White 6,300 54.3 (52.4–56.2)
 Non-Hispanic Black 840 14.1 (12.8–15.6)
 Hispanic 1,461 22.8 (21.0–24.7)
 American Indian/Alaskan Native 147 0.9 (0.7–1.3)
 Asian 278 3.1 (2.5–3.8)
 Other 528 4.7 (4.1–5.4)
Mother’s educational level
 <High School 1,054 13.9 (12.5–15.5)
 High School 1,695 24.3 (22.5–26.1)
 Some college or college graduate 2,631 25.6 (24.0–27.1)
 >College graduate 4,174 36.2 (34.5–38.0)
Mother’s married status
 Married 6,919 66.7 (64.9–68.5)
 Widowed/divorced/separated 1,809 22.8 (21.2–24.4)
 Never married 750 10.5 (9.3–11.9)
Mother’s age
 ≤34 years 834 9.6 (8.6–10.7)
 35–44 years 4,043 45.2 (43.3–47.1)
 ≥45 years 4,677 45.2 (43.3–47.0)
Immigration status
 Born in U.S. 9,206 95.3 (94.1–96.2)
 Born outside U.S. 323 4.7 (3.8–5.9)
Income to poverty ratio
 <1.33% 2,366 34.0 (32.1–36.0)
 1.33% – <3.22% 2,856 30.3 (28.6–32.1)
 3.22% – <5.03% 2,118 17.1 (15.9–18.4)
 >5.03% 2,214 18.5 (17.3–19.9)
Medical insurance†
 Private insurance only 4,609 42.0 (40.3–43.9)
 VFC Eligible-Medicaid/IHS/AIAN(All) 3,827 45.3 (43.4–47.2)
 VFC Eligible-Uninsured 469 6.0 (5.1–7.0)
 SCHIP(Public) 269 2.9 (2.4–3.5)
 Military 314 2.9 (2.4–3.5)
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Characteristic Sample %*
 Other 66 0.9 (0.5–1.8)
Physician contacts within past year
 None 1,468 18.0 (16.5–19.6)
 1 2,777 28.6 (26.9–30.3)
 2–3 3,365 34.7 (32.9–36.6)
 ≥4 1,902 18.7 (17.3–20.1)
Well child visit at age 11–12 years‡
 Yes 3,318 34.3 (32.5–36.1)
 No 1,829 16.9 (15.7–18.2)
 Not licensed§ 2,182 22.7 (21.2–24.3)
 Don’t know 2,225 26.2 (24.4–28.0)
Number of providers
 1 4,757 50.7 (48.9–52.6)
 2 2,842 28.9 (27.2–30.6)
 ≥3 1,943 20.4 (18.8–22.0)
Metropolitan statistical area (MSA)
 Urban area 3,636 38.9 (37.1–40.8)
 Suburban area 3,743 47.7 (45.8–49.6)
 Rural area 2,175 13.4 (12.5–14.4)
Region
 Northeast 1,975 16.9 (16.0–17.8)
 Midwest 2,174 21.7 (20.7–22.7)
 South 3,132 37.5 (36.0–39.0)
 West 2,273 24.0 (22.3–25.7)
Facility type
 All private facilities 4,470 52.2 (50.3–54.1)
 All public facilities 1,398 14.8 (13.4–16.3)
 All hospital facilities 993 9.0 (8.0–10.2)
 All STD/school/teen clinics or other facilities 160 1.8 (1.4–2.3)
 Mixed|| 2,343 21.0 (19.6–22.5)
 Other¶ 141 1.2 (0.9–1.6)
*
Percentages are weighted.
†
Insurance categories are mutually exclusive.
‡Status of health-care visit at age 11–12 years based on provider reported data.
§
This indicated that the adolescents were ≥13 years of age when HPV vaccination was recommended in 2006.
||
Mixed indicates that the facility is identified to be in more than one of the facility categories such as private, public, hospital, STD/school/teen 
clinics.
¶
Includes military, WIC clinics, and pharmacies.
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